Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALA-SCALP vs AEROSEB-HC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ALA-SCALP (aminolevulinic acid) is a photosensitizer precursor that is converted intracellularly to protoporphyrin IX (Pp IX), which accumulates in cells with increased heme synthesis, such as rapidly dividing cells. Upon exposure to blue light (BLU-U®), Pp IX produces reactive oxygen species, leading to cellular damage and apoptosis of targeted cells.
AEROSEB-HC (hydrocortisone/iodoquinol) exerts anti-inflammatory, antipruritic, and antifungal actions. Hydrocortisone suppresses inflammatory mediators via glucocorticoid receptor binding, while iodoquinol provides antimicrobial activity against dermatophytes and bacteria.
Treatment of minimally to moderately thick actinic keratoses of the scalp (Grade 1 or 2) in immunocompetent patients,Off-label: other photosensitivity disorders
FDA-approved for the treatment of eczematous dermatitis, atopic dermatitis, and other glucocorticoid-responsive dermatoses complicated by fungal or bacterial infections
Topical application of a 5% solution to the scalp twice daily.
AEROSEB-HC (hydrocortisone/iodoquinol) topical cream: Apply a thin film to affected area twice daily for up to 7 days. Not for ophthalmic or oral use.
Not applicable; topical ALA-SCALP is not significantly absorbed systemically. After systemic absorption from photodynamic therapy, terminal half-life is approximately 1 hour due to rapid metabolism.
1.5-2 hours (terminal) after intravenous administration; prolonged in hepatic impairment.
ALA is metabolized intracellularly via the heme biosynthesis pathway to protoporphyrin IX (Pp IX).
Hydrocortisone is primarily hepatic via CYP3A4; iodoquinol is not extensively metabolized, with partial glucuronidation and enterohepatic circulation.
Primarily renal elimination of metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion is negligible.
Renal (primarily as metabolites; <5% unchanged); fecal (biliary excretion of metabolites).
Not characterized; systemic levels are negligible after topical administration.
90-95% (albumin and corticosteroid-binding globulin).
Not applicable for topical route. If systemic exposure occurs, Vd is approximately 0.5 L/kg, consistent with distribution into total body water.
0.4-0.6 L/kg; indicates distribution into total body water and tissues.
Topical: Systemic bioavailability is minimal (<1%) due to poor percutaneous absorption and rapid local metabolism.
Oral: 80-90%; Intramuscular: 100%; Intravenous: 100%.
No dose adjustment required for renal impairment.
No adjustment required for topical application. Systemic absorption is minimal; however, in severe renal impairment (GFR <30 m L/min), use caution due to potential systemic corticosteroid effects.
No dose adjustment required for hepatic impairment.
No specific adjustment for topical use. In Child-Pugh C cirrhosis, consider the risk of systemic corticosteroid accumulation; use with caution.
Safety and efficacy in pediatric patients have not been established.
Children >2 years: Apply a thin film to affected area twice daily for up to 7 days. Avoid prolonged use, occlusion, or application to large body surface areas. Safety in children <2 years not established.
No specific dose adjustment recommended; use with caution due to potential increased sensitivity.
Elderly patients: Use the lowest effective duration and avoid prolonged use due to increased risk of skin atrophy and systemic absorption. Apply sparingly to limited areas.
No FDA black box warning.
None
Photosensitivity: avoid exposure to sunlight or bright indoor light (e.g., examination lamps, operating room lamps) for at least 40 hours post-application.,Application site reactions: severe stinging, burning, erythema, and edema may occur.,Use sun-protective measures (e.g., wide-brimmed hat, sunscreen) after treatment.,Do not apply to eyes or mucous membranes.
Prolonged use may lead to systemic corticosteroid effects, including HPA axis suppression, Cushing's syndrome, and hyperglycemia.,Risk of secondary infection due to immunosuppression.,Local adverse reactions such as skin atrophy, striae, and perioral dermatitis.,Avoid use in diaper area or under occlusive dressings.
Hypersensitivity to aminolevulinic acid or any component of the formulation,Cutaneous photosensitivity at wavelengths of 400-450 nm,Porphyria
Hypersensitivity to any component (hydrocortisone, iodoquinol, or sulfites).,Viral or fungal infections without appropriate antimicrobial coverage.,Immunocompromised patients (systemic use relative).,Pregnancy (category C, use only if benefit outweighs risk).
No known food interactions. No dietary restrictions required.
No clinically significant food interactions are reported for topical hydrocortisone/pramoxine. No dietary restrictions necessary.
No evidence of teratogenicity; topical application with minimal systemic absorption. First trimester: unlikely risk. Second/third trimester: no known fetal risks from maternal use.
FDA Pregnancy Category C. First trimester: limited data, no increased risk of major malformations identified in small studies. Second and third trimesters: potential for fetal adrenal suppression with prolonged use; avoid high doses and prolonged exposure.
Minimal systemic absorption; unlikely to appear in breast milk. M/P ratio not established. Considered compatible with breastfeeding.
Present in breast milk in low concentrations. M/P ratio not determined. Use with caution, especially with high doses or prolonged treatment; risk of infant adrenal suppression theoretical.
No dosage adjustment required; pharmacokinetics unlikely altered due to topical route.
No standard dose adjustments required for pregnancy-related pharmacokinetic changes. Use lowest effective dose for shortest duration. Avoid high-dose or prolonged use in pregnancy.
ALA-SCALP is a topical aminolevulinic acid preparation used for photodynamic therapy of actinic keratoses on the scalp. Must be applied by a healthcare professional. Avoid sun exposure to treated area for 48 hours post-application due to photosensitivity. Do not apply to eyes or mucous membranes. Lesions should be prepped by gentle removal of scales and crusts. Use with a compatible light source (blue light). Burning and stinging during light exposure is common; consider pain management strategies.
AEROSEB-HC is a combination aerosol foam containing hydrocortisone acetate 1% and pramoxine hydrochloride 1% for topical use. It is indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, particularly in anogenital areas. The foam formulation enhances penetration and is less messy than ointments. Advise patients to avoid contact with eyes and mucous membranes. Use with caution in patients with skin infections or atrophy. Prolonged use in intertriginous areas may increase risk of local and systemic adverse effects.
This medication is applied by your doctor to treat precancerous spots on your scalp.,After application, you will need a special light treatment (photodynamic therapy).,Avoid sunlight and bright indoor light on the treated area for 48 hours after the procedure.,You may experience temporary redness, swelling, scaling, or discomfort at the treatment site.,Use sunscreen and protective clothing when going outdoors during the photosensitivity period.,Do not wash the treated area for at least 4 hours after the solution is applied.,Contact your doctor if you experience severe pain, blistering, or signs of infection.
Apply a small amount to the affected area as directed, usually 2-4 times daily.,Do not cover the area with bandages or dressings unless instructed by your doctor.,Avoid use on broken skin, open wounds, or infected areas unless specifically prescribed.,Do not use for more than 2 weeks without medical supervision, especially in the anogenital region.,If symptoms do not improve or worsen, contact your healthcare provider.,Keep away from eyes, mouth, and other mucous membranes.,Wash hands after applying unless treating hands.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALA-SCALP vs AEROSEB-HC, answered by our medical review team.
ALA-SCALP is a Topical Corticosteroid that works by ALA-SCALP (aminolevulinic acid) is a photosensitizer precursor that is converted intracellularly to protoporphyrin IX (Pp IX), which accumulates in cells with increased heme synthesis, such as rapidly dividing cells. Upon exposure to blue light (BLU-U®), Pp IX produces reactive oxygen species, leading to cellular damage and apoptosis of targeted cells.. AEROSEB-HC is a Topical Corticosteroid that works by AEROSEB-HC (hydrocortisone/iodoquinol) exerts anti-inflammatory, antipruritic, and antifungal actions. Hydrocortisone suppresses inflammatory mediators via glucocorticoid receptor binding, while iodoquinol provides antimicrobial activity against dermatophytes and bacteria.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALA-SCALP and AEROSEB-HC depend on the specific clinical indication. These are both Topical Corticosteroid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALA-SCALP is: Topical application of a 5% solution to the scalp twice daily.. The standard adult dose of AEROSEB-HC is: AEROSEB-HC (hydrocortisone/iodoquinol) topical cream: Apply a thin film to affected area twice daily for up to 7 days. Not for ophthalmic or oral use.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALA-SCALP and AEROSEB-HC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALA-SCALP is classified as Category C. No evidence of teratogenicity; topical application with minimal systemic absorption. First trimester: unlikely risk. Second/third trimester: no known fetal risks from maternal use.. AEROSEB-HC is classified as Category C. FDA Pregnancy Category C. First trimester: limited data, no increased risk of major malformations identified in small studies. Second and third trimesters: potential for fetal adre. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.